^
Association details:
| Biomarker: | GRB7 positive |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study
Published date:
12/06/2019
Excerpt:
...Patients with...(Grb7) –positive tumors at baseline demonstrated significantly better survival (P = .007) or treatment response (P = .016), respectively...Three-year progression-free and overall survival (OS) were 57% and 71%, respectively (median follow-up, 32.1 months)....Addition of trastuzumab and pertuzumab to nCRT in patients with HER2-positive EAC is feasible and demonstrates potentially promising activity compared with historical controls.
Secondary therapy:
carboplatin + bisphosphonate bound paclitaxel
DOI:
10.1200/JCO.19.01814
